

JAAD Consultative Dermatology—Relaunched



Lucia Seminario-Vidal, MD, PhD,^{a,b} Lindy P. Fox, MD,^c Jane M. Grant-Kels, MD,^d and Dirk Elston, MD^e
Tampa, Florida; San Francisco, California; Farmington, Connecticut; and Charleston, South Carolina

Key words: commentary; complex medical dermatology; consultative dermatology; dermatology consultation; dermatology hospitalist; inpatient dermatology; original article; research letter.

This month, the *Journal of the American Academy of Dermatology* (JAAD) is relaunching the Consultative Dermatology section with an article on complex purpura from Gehlhausen et al.¹ This section was initially launched in 2017 with the goal of addressing issues related to the care of patients with complex medical dermatology conditions in both outpatient and inpatient settings. We relaunch this section with the goal of increasing awareness of the critical role of dermatologists within the House of Medicine through the publication of articles related to the diagnosis and management of complex dermatologic disease. Dermatology was one of the first 4 recognized medical specialties in the United States because there has always been a need for special expertise in the diagnosis and treatment of skin disease. We have entered a new age of medical therapy with highly effective targeted drugs for malignancy, new immunomodulating agents, and a vast array of new biologics. Our specialty has been at the cutting edge of these developments, with effective therapies for conditions ranging from metastatic melanoma to refractory dermatomyositis and autoinflammatory disorders. Our expertise is also key to the management of the many cutaneous adverse effects of these new agents.

The JAAD Consultative Dermatology section's goal aligns with the American Academy of Dermatology's SkinSerious campaign and the missions of its sister societies, including the Society of Dermatology Hospitalists and the Medical

Dermatology Society. The American Academy of Dermatology's National Burden of Skin Disease Report estimated a direct cost of \$75 billion for the treatment of skin disease, with 75% of these costs related to outpatient services.^{2,3} We treat some of medicine's most challenging disorders, and the explosion in available diagnostic tools and an expanded therapeutic armamentarium have improved patient outcomes.

We welcome articles that focus on the diagnosis and management of complex dermatologic disease and address existing practice gaps. Articles that appeal to a multispecialty audience are encouraged, and we will make selected high-impact articles open access to increase their reach. Brevity and focus are key, and supplemental material can be hosted on Mendeley with a link in the print or online versions of the article. Instructions for original studies, research letters, and review articles can be found in the JAAD author guidelines (available at https://www.jaad.org/content/auth_page). JAAD no longer publishes case reports, but our sister journal *JAAD Case Reports* welcomes unique case reports and case series. *JAAD International* welcomes submissions that focus on diseases and therapeutics of predominant interest to an international audience, and its open access model provides the widest international access to those important articles. The JAAD family of journals seeks to improve patient outcomes by providing dermatologists with game-changing scientific advances that improve patient care. Please watch for and send

From the Department of Dermatology, University of South Florida^a; Department of Cutaneous Oncology, Moffitt Cancer Center^b; Department of Dermatology, University of California, San Francisco^c; Dermatology Department, University of Connecticut, Farmington^d; and Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina.^e

Funding sources: None.

Conflicts of interest: None disclosed.

IRB approval status: Not applicable.

Reprints are not available from the authors.

Correspondence to: Lindy P. Fox, MD, Department of Dermatology, University of California, San Francisco, 1701 Divisadero St, 3rd Floor, Box 0316, San Francisco, CA, 94115. E-mail: lindy.fox@ucsf.edu.

J Am Acad Dermatol 2021;84:905-6.
0190-9622/\$36.00

© 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2020.08.104>

your best work to our Consultative Dermatology section to help advance our specialty and improve care for our patients with the most challenging conditions.

REFERENCES

1. Gehlhausen JR, Wetter DA, Nelson C, Ramachandran S, McNiff JM, Ko CJ. A detailed analysis of the distribution, morphology, and histopathology of complex purpura in hospitalized patients: A case series of 68 patients. *J Am Acad Dermatol.* 2021;84:1188-1196.
2. Lim HW, Collins SAB, Resneck JS Jr, et al. The burden of skin disease in the United States. *J Am Acad Dermatol.* 2017;76(5):958-972.
3. Lim HW, Collins SAB, Resneck JS Jr, et al. Contribution of healthcare factors to the burden of skin disease in the United States. *J Am Acad Dermatol.* 2017;76:1151-1160.

Dermatology COVID registry: We need your help to answer critical questions about vaccine reactions

The Dermatology COVID-19 Registry is collecting data on cutaneous COVID-19 vaccine reactions.

The registry is supported by the American Academy of Dermatology and the International League of Dermatological Societies, and is available online through the AAD website at www.aad.org/covidregistry. Any health care worker can enter a case, data entry takes 5 to 7 minutes, and no patient-protected health information is required.

Special thanks to principal investigator Esther Freeman, MD, PhD and staff at Harvard and the AAD for creating this resource.

Please enter any vaccine reactions you see into the registry.